Abstract
The relationship between the antithrombotic effects of intravenous infusions of YM-75466 [N-[4-[(1-acetimidoyl-4-piperidyl)oxy]phenyl]-N-[(7-amidino-2-naph thyl)methyl] sulfamoyl]acetic acid monomethanesulfonate), a novel factor Xa (FXa) inhibitor, and various coagulation parameters (prothrombin time, activated partial thromboplastin time, thrombin-antithrombin III complex (TAT), anti-FXa activity and anti-thrombin activity) in rats was studied and compared with results for heparin. In the arterio-venous shunt model, both agents exerted antithrombotic effects in a dose-dependent manner. Coagulation parameters were studied simultaneously with antithrombotic effects. YM-75466 did not prolong coagulation time even at the dose which exerted significant antithrombotic effects, while it decreased TAT level in plasma in a dose-dependent manner. YM-75466 exerted anti-FXa activity but not anti-thrombin activity. In contrast, heparin prolonged activated partial thromboplastin time in a dose-dependent manner and decreased TAT level in plasma with increasing inhibition of thrombus formation. Heparin exerted both anti-FXa and anti-thrombin activity in a dose-dependent manner. These results suggest that TAT is a suitable parameter for monito...Continue Reading
References
Jun 1, 1992·Thrombosis Research·K KarioM Matsuo
Feb 1, 1992·Circulation·G R SitkoG P Vlasuk
Jul 1, 1991·British Journal of Haematology·M EstivalsB Boneu
Oct 1, 1991·American Journal of Hematology·K DeguchiK Tanaka
Jul 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·C RavanatC Legrand
Jun 1, 1996·Arteriosclerosis, Thrombosis, and Vascular Biology·K KarioM Matsuo
Dec 1, 1995·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·I MacGregorO Drummond
Jul 15, 1996·Thrombosis Research·P C WongA Racanelli
Feb 24, 1998·European Journal of Pharmacology·K SatoY Matsumoto
Mar 4, 1998·British Journal of Pharmacology·K SatoY Matsumoto
Citations
Dec 13, 2001·European Journal of Pharmacology·T B McClanahanR Leadley
Sep 30, 2000·Thrombosis Research·V ChuC T Dunwiddie
Sep 20, 2001·Thrombosis Research·V ChuR J Leadley
Mar 13, 1999·Thrombosis Research·J Hauptmann, J Stürzebecher
Jan 11, 2001·Journal of Pharmacological and Toxicological Methods·R J LeadleyA Gagnon
Jun 17, 2011·Cardiovascular Research·Martina DelbeckGeorges von Degenfeld
Oct 19, 2001·Chemical & Pharmaceutical Bulletin·H NishidaH Mochizuki
Sep 19, 2002·Chemical & Pharmaceutical Bulletin·Hidemitsu NishidaHidenori Mochizuki
Sep 12, 2000·Current Cardiology Reports·F A Spencer, R C Becker
Nov 2, 2011·European Journal of Pharmacology·Yoshiyuki IwatsukiSeiji Kaku
Mar 8, 2005·Journal of Thrombosis and Haemostasis : JTH·E PerzbornA Straub
Mar 5, 2008·Journal of Thrombosis and Haemostasis : JTH·P C WongR M Knabb
May 15, 2012·Expert Opinion on Drug Metabolism & Toxicology·Lakshmi GopalakrishnanC Michael Gibson
Oct 1, 2016·European Journal of Medicinal Chemistry·Junhao XingHuibin Zhang
Mar 12, 2002·Bioorganic & Medicinal Chemistry·Fukushi HirayamaIsao Yanagisawa
Jun 12, 2002·Bioorganic & Medicinal Chemistry·Fukushi HirayamaShin-ichi Tsukamoto
Nov 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Pancras C WongRobert M Knabb
Aug 15, 2002·Cardiovascular Drug Reviews·Pancras C WongRobert M Knabb
Dec 23, 2004·Journal of Thrombosis and Haemostasis : JTH·K KarnickiJ H Chesebro
Jan 27, 2005·Bioorganic & Medicinal Chemistry·Hiroyuki KoshioShin-ichi Tsukamoto
Sep 16, 2005·Journal of Medicinal Chemistry·Susanne RoehrigElisabeth Perzborn